Asenapine for Bipolar Depression

Sponsor

University of Cincinnati (Other)

Overall Status

Terminated

CT.gov ID

NCT01807741

Collaborator

University of Louisville (Other), Merck Sharp & Dohme LLC (Industry)

Enrollment

Location

Arms

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks.

We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.

Condition or Disease	Intervention/Treatment	Phase
Bipolar Depression	Drug: Asenapine Drug: Placebo	Phase 2

Detailed Description

86 patients with an episode of major depression associated with bipolar disorder, type I will be recruited by two sites for the study over fifteen months. Medication will be administered in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at 5 mg bid. Dose may be increased to 10 mg bid and adjusted based on clinical response. Patients will be evaluated by a blinded (to treatment status) rater. Patients will be seen and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42, and 56 (or termination from the study). Adverse events will be evaluated as well.

Study Design

Study Type:

Interventional

Actual Enrollment :

51 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Asenapine for Bipolar Depression

Study Start Date :

Sep 1, 2013

Actual Primary Completion Date :

Jul 1, 2017

Actual Study Completion Date :

Jul 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Asenapine Group Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.	Drug: Asenapine Available in 5 and 10 mg. Other Names: Saphris
Active Comparator: Placebo Group Sublingual tablets similar to the asenapine tablets.	Drug: Placebo Other Names: sugar pill

Arm

Intervention/Treatment

Experimental: Asenapine Group

Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.

Drug: Asenapine

Available in 5 and 10 mg.

Other Names:

Saphris

Active Comparator: Placebo Group

Sublingual tablets similar to the asenapine tablets.

Drug: Placebo

Other Names:

sugar pill

Outcome Measures

Primary Outcome Measures

Change in Depression Score [8 weeks]
The Montgomery-Asberg Depression Rating Scale (MADRS)will be used as a measure of efficacy reflecting change in MADRS total scores from baseline to endpoint over 8 weeks.

Secondary Outcome Measures

Change in Depression Response Rate [8 weeks]
MADRS Response Rate: Defined by a ≥ 50% decrease from baseline to endpoint in MADRS total score over 8 weeks.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Meet criteria for bipolar depression based on the MINI and confirmation of a previous manic or mixed episode
18-55 years of age
Female patients must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence)
Each patient must understand the nature of the study and must provide written informed consent
Patients must have a diagnosis of bipolar disorder, type I and currently display an acute depressive episode as determined by M.I.N.I. (Sheehan et al, 1998)
Patients must have a baseline (day 0) MADRS score ≥26
Current episode of depression must have persisted for at least one month and no more than six months at study entry
Subjects should be fluent in English

Exclusion Criteria:

Female patients who are either pregnant or lactating
Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions
Any history of current or past diabetes that was treated with pharmacological intervention
Neurological disorders including epilepsy, stroke, or severe head trauma
Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, thyroid indices and EKG
Depression due to a general medical condition or substance-induced depression (DSM-IV)
Mental retardation (IQ <70)
Meeting criteria for a mixed episode, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
History of hypersensitivity to or intolerance of asenapine
Prior history of asenapine non-response
DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months
Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline MADRS suicide score of >4)
Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry
Failure of the current depressive episode to respond to two or more pharmacological interventions
Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0
Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV
Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified